J. Dasseux

发表

Metabolomics applications of FT-ICR mass spectrometry.

G. Kruppa, Stephen C Brown, Gary Kruppa, 2005, Mass spectrometry reviews.

The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.

D. Gaudet, J. Kastelein, E. Stroes, 2015, American heart journal.

HDL mimetic CER-001 targets atherosclerotic plaques in patients.

Z. Fayad, G. V. van Dongen, R. Duivenvoorden, 2016, Atherosclerosis.

The effect of an Apolipoprotein A-I- containing HDL-mimetic Particle (CER-001) on carotid artery wall thickness in Patients with Homozygous Familial Hypercholesterolemia

D. Gaudet, J. Kastelein, E. Stroes, 2015 .

Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA[S]

J. Kastelein, G. Hovingh, A. Nederveen, 2015, Journal of Lipid Research.

Effect of open-label infusion of an apolipoprotein A-I-containing particle ( CER-001 ) on reverse cholesterol transport and artery wall thickness in patients with familial hypo-alphalipoproteinemia

J. Kastelein, R. Santos, E. Stroes, 2014 .

Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

S. Nicholls, R. Puri, J. Paolini, 2017, Cardiovascular diagnosis and therapy.

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings

C. Keyserling, R. Barbaras, J. Dasseux, 2017, Clinical Drug Investigation.

Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial

J. Kastelein, B. Merkely, S. Nissen, 2018, JAMA cardiology.

P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo

N. Lalwani, C. Tardy, N. Boubekeur, 2014, PloS one.

CER-001 ameliorates lipid profile and kidney disease in a mouse model of Familial LCAT Deficiency.

F. Veglia, C. Zoja, M. Locatelli, 2020, Metabolism: clinical and experimental.

HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation

J. Paolini, N. Lalwani, C. Tardy, 2015, PloS one.

CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.

J. Paolini, N. Lalwani, C. Tardy, 2014, Atherosclerosis.

No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels.

D. Gaudet, R. Hegele, A. Nederveen, 2020, Atherosclerosis.

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

J. Kastelein, B. Merkely, S. Nissen, 2017, Cardiovascular diagnosis and therapy.

Morphological changes of phosphatidylcholine bilayers induced by melittin: vesicularization, fusion, discoidal particles.

G. Fourche, J. Dufourcq, M. le Maire, 1986, Biochimica et biophysica acta.

A restatement of melittin-induced effects on the thermotropism of zwitterionic phospholipids.

M. Lafleur, J. Dufourcq, M. Pézolet, 1984, Biochimica et biophysica acta.

The amphipathic α‐helix concept

J. Dufourcq, J. Dasseux, I. Cornut, 1994 .

Effects of bee venom melittin on the order and dynamics of dimyristoylphosphatidylcholine unilamellar and multilamellar vesicles.

T. D. Bradrick, S. Georghiou, J. Dasseux, 1987, Biochimica et biophysica acta.

Syntheses of Pantolactone and Pantothenic Acid Derivatives as Potential Lipid Regulating Agents

M. Pape, C. Bisgaier, R. Mueller, 2006 .

The amphipathic helix concept: length effects on ideally amphipathic LiKj(i=2j) peptides to acquire optimal hemolytic activity.

J. Dufourcq, S. Castano, J. Dasseux, 1999, Biochimica et biophysica acta.

Study of the effect of melittin on the thermotropism of dipalmitoylphosphatidylcholine by Raman spectroscopy.

M. Lafleur, J. Dufourcq, M. Pézolet, 1987, Biochemistry.

Lipoproteins for therapeutic delivery: recent advances and future opportunities.

N. Sabnis, Sangram Raut, A. Lacko, 2018, Therapeutic delivery.

Interaction of the pore-forming domain of colicin A with phospholipid vesicles.

F. Pattus, D. Massotte, K. Leonard, 1989, Biochemistry.

Membrane insertion of the pore-forming domain of colicin A. A spectroscopic study.

M. Parker, J. Lakey, F. Pattus, 1991, European journal of biochemistry.

The amphipathic alpha-helix concept. Application to the de novo design of ideally amphipathic Leu, Lys peptides with hemolytic activity higher than that of melittin.

J. Dufourcq, J Dufourcq, I Cornut, 1994, FEBS letters.

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

M. Pfeffer, C. Grines, R. D. de Winter, 2014, European heart journal.

Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): The modifying orphan disease evaluation (mode) study

D. Gaudet, E. Stroes, J. Paolini, 2014 .

HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits.

J. Tardif, É. Rhéaume, N. Lalwani, 2016, International journal of cardiology.

Lipophilicity parameters and biological activity in a series of compounds with potential cardiovascular applications

M. Pape, E. Pop, D. Oniciu, 2004 .

HDL mimetic CER-001 targets atherosclerotic plaques in patients.

Z. Fayad, G. V. van Dongen, R. Duivenvoorden, 2016, Atherosclerosis.

Lipid-Protein Interactions: A Reinvestigation of Melittin Induced Effects on the Structure and Dynamics of Phosphatidylcholines

M. Lafleur, J. Dufourcq, M. Maire, 1986 .